<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607802</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU-99107</org_study_id>
    <secondary_id>CDR0000584624</secondary_id>
    <secondary_id>IRB00002178</secondary_id>
    <nct_id>NCT00607802</nct_id>
  </id_info>
  <brief_title>Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer</brief_title>
  <official_title>White Cell Transfer as Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects of donor white blood cell infusion&#xD;
      in treating patients with metastatic or unresectable cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of white blood cell infusion in patients with metastatic or&#xD;
           unresectable cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the efficacy of this therapy in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive allogeneic white blood cell infusions once daily for 5-10&#xD;
      infusions.&#xD;
&#xD;
      Patients undergo blood sample collection periodically for correlative laboratory studies. The&#xD;
      samples are evaluated by in vitro white cell kill assay before the first infusion,&#xD;
      immediately after the first infusion, on day 2, and then immediately after the last infusion&#xD;
      to assess in vitro cancer cell killing activity. Chimerism studies are performed before the&#xD;
      first infusion, immediately after the first infusion, and then on days 2 and 7. Complete&#xD;
      chimerism is assayed by short tandem repeat analysis using PCR. Patients with readily&#xD;
      accessible tumor tissue (e.g., cervical or axillary lymph nodes or subcutaneous tumor&#xD;
      nodules) may also undergo biopsy during the first week of treatment to demonstrate the&#xD;
      presence or absence of tumor infiltrating granulocytes.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response (complete response, partial response, stable disease, or disease progression)</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>leukocyte therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignancy&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
               -  Standard curative or palliative measures do not exist or are no longer effective&#xD;
&#xD;
          -  Measurable or non-measurable disease&#xD;
&#xD;
               -  Measurable disease is defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm&#xD;
                  by conventional techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Non-measurable disease is defined as all other lesions (including small lesions&#xD;
                  and truly non-measurable lesions), including any of the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No brain metastasis&#xD;
&#xD;
          -  Healthy blood donor available meeting the following criteria:&#xD;
&#xD;
               -  Willing to be included in the White Cell Donor Registry created for this study&#xD;
&#xD;
               -  Willing to undergo granulocyte apheresis at the American Red Cross&#xD;
&#xD;
               -  ABO compatible with the patient&#xD;
&#xD;
               -  HLA-mismatched with the patient&#xD;
&#xD;
               -  Demonstrates ≥ 60% cytotoxic killing activity (CKA) as determined by in vitro&#xD;
                  white cell kill assay&#xD;
&#xD;
                    -  Less than 60% CKA allowed if deemed suitable by the investigators&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 4 months&#xD;
&#xD;
          -  ANC ≥ 1,000/µL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/µL (platelet transfusion independent)&#xD;
&#xD;
          -  Serum bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Serum creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No myocardial infarction within the past 30 days&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  No HIV infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Negative panel reactive antibody test (i.e., absence of serum HLA antibody)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior fludarabine phosphate&#xD;
&#xD;
          -  No prior stem cell transplantation&#xD;
&#xD;
          -  At least 4 weeks since prior medical therapy, radiotherapy, or surgery&#xD;
&#xD;
          -  More than 30 days since prior immunosuppressive agents other than steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng Cui, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>January 30, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

